Novel Therapeutics for Rare Fungal Infections
F2G (Functional Fungal Genomics) is a clinical-stage biopharmaceutical company based in Manchester, UK, focused on developing first-in-class medicines for rare, life-threatening fungal infections. The company discovered and developed the orotomides, a novel class of antifungal agents that selectively target a key enzyme in fungal metabolism, with lead candidate olorofim advancing through late-stage development.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountSep 2024
Aug 2022
Aug 2020
Sep 2012
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
